Pharvaris N.V. (PHVS)

NL — Healthcare Sector
Peers: MOLN  PMVP  EWTX  RLYB  VOR  IMCR 

Automate Your Wheel Strategy on PHVS

With Tiblio's Option Bot, you can configure your own wheel strategy including PHVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PHVS
  • Rev/Share 0.0
  • Book/Share 4.1332
  • PB 4.1025
  • Debt/Equity 0.0033
  • CurrentRatio 11.0999
  • ROIC -0.1348

 

  • MktCap 924019497.7323
  • FreeCF/Share -2.4769
  • PFCF -6.8426
  • PE -6.0603
  • Debt/Assets 0.003
  • DivYield 0
  • ROE -0.5435

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PHVS Guggenheim -- Buy -- $32 June 11, 2025
Initiation PHVS Cantor Fitzgerald -- Overweight -- $28 April 29, 2025

News

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
PHVS
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

ZUG, Switzerland, June 02, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop.

Read More
image for news Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
PHVS
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy …

Read More
image for news Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
PHVS
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema

Read More
image for news Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

About Pharvaris N.V. (PHVS)

  • IPO Date 2021-02-05
  • Website https://pharvaris.com
  • Industry Biotechnology
  • CEO Berndt Axel Edvard Modig CPA,
  • Employees 108

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.